Imagenebio, Inc. · NASDAQ:IMA
Imagenebio — Investor Presentation (November 2025)
25 slides from Imagenebio's investor presentation, Nov 19, 2025
Slide 1: ImageneBio Corporate Overview Fourth Quarter 2025
Exhibit 99.1 ImageneBio Corporate Overview Fourth Quarter 2025
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This investor presentation and any accompanying oral commentary have been prepared by ImageneBio, Inc. (the Company) for informational purposes only and not for any other purpose. This investor presentation and any accompanying oral commentary contain forwar
Slide 3: Innovating in immunology
Innovating in immunology Established as a public company (NASDAQ: Anchored on IMG-007, a differentiated anti- IMA) in July 2025 through Inmagene-Ikena OX40 monoclonal antibody (mAb) in Phase 2b reverse merger and concurrent financing for atopic dermatitis, the most common type of eczema Well-funded
Slide 4: In the large atopic dermatitis population, patients are being underserved
In the large atopic dermatitis (AD) population, patients are being underserved 1 As of today, it is estimated that there are… The global AD biologics market is estimated at $15 billion in 2025, and People living in the US with AD 26 million 2 growing year-over-year Children living in the US with AD
Slide 5: OX40 signaling plays a central role in inflammation
OX40 signaling plays a central role in inflammation, with involvement across multiple T cell subtypes • OX40 is a receptor protein that is highly expressed on various subtypes of activated T cells • Markers of these T cells are found in the circulating bloodstreams and skin of patients with atopic d
Slide 6: OX40's role across T cell subsets underscores its potential in atopic dermatitis
OX40’s role across T cell subsets underscores its potential in atopic dermatitis • Atopic dermatitis is well known as a heterogeneous disease where patients can have multiple pathways over-activated simultaneously • Inhibiting OX40/OX40L signal cascade is a promising novel therapeutic approach becau
Slide 7: Designed to be different: IMG-007, a next generation anti-OX40 mAb
Designed to be different: IMG-007, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile IMG-007 has a trifecta of 2. T cell-preserving for safety and tolerability differentiating features 3. Extended half-life for patient- and physician-friendly dosing schedules 7
Slide 8: Designed to be different: IMG-007, a next generation anti-OX40 mAb
Designed to be different: IMG-007, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows IMG-007 to inhibit OX40-OX40L signaling in both blood and tissues. 2. T cell-preserving for safety and tolerabil
Slide 9: Designed to be different: IMG-007, a next generation anti-OX40 mAb
Designed to be different: IMG-007, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Illustrative OX40/OX40L Interaction Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows IMG-007 to inhibit OX40-OX40L signaling in both blood and tissues. 2. T cell
Slide 10: Designed to be different: IMG-007, a next generation anti-OX40 mAb
Designed to be different: IMG-007, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Half-Life Targeting OX40 receptor (OX40) rather than OX40 ligand (OX40L) allows IMG-007 to inhibit OX40-OX40L signaling in both blood and tissues. Roca 2. T cell-preserving for safet
Slide 11: Designed to be different: IMG-007, a next generation anti-OX40 mAb
Designed to be different: IMG-007, a next generation anti-OX40 mAb 1. Receptor targeting for optimal efficacy profile Efficacy, safety, and convenience all drive IMG-007 has a product choice among physicians and patients in trifecta of inflammatory and autoimmune disease 2. T cell-preserving for saf
Slide 12: IMG-007 has best-in-class potential among OX40/OX40L antagonists
Next generation IMG-007 has best-in-class potential among OX40/OX40L antagonists OX40 Targeting Optimization IMG-007 (Ph2b) Rocatinlimab (Ph3) Amlitelimab (Ph3) Receptor Targeting✓✓ X (Ligand-targeting) Optimized Half-Life ~5 weeks ~1.5 weeks ~3 weeks Non-T Cell Depleting✓ X✓ IMG-007 is designed to
Slide 13: IMG-007 Phase 1b/2a in adults with moderate-to-severe AD enrolled a typical population
IMG-007 Phase 1b/2a in adults with moderate-to-severe atopic dermatitis (AD) enrolled a typical patient population Patient demographics, n=13 Mean Age, years (SD): 49.8 (15.0) • IMG-007 monotherapy Gender: Female 31%, Male 69% Mean BMI (SD): 31.4 (8.7) • No topical or systemic AD medications allowed
Slide 14: IMG-007 proof of concept: rapid improvement in AD skin signs
IMG-007 proof of concept: notable, rapid improvement in AD skin signs among treated patients in Phase 1b/2a Mean percent (%) change from baseline in BSA score Mean percent (%) change from baseline in EASI score Four-week IMG-007 treatment with only three doses resulted in 87% mean reduction in EASI
Slide 15: Majority of patients achieved EASI-75 and almost one third achieved EASI-90
The majority of patients achieved 75% or more and almost one third achieved 90% or more improvement in EASI score by week 16 • EASI-75, a 75% improvement Proportion of patients achieving EASI-75 and EASI-90 in EASI score or better, was achieved by 54%, 54% and 46% of participants at weeks 16, 20, an
Slide 16: Early IMG-007 data support a favorable emerging safety profile
Early IMG-007 data support a favorable emerging safety profile; no fever or chills observed Treatment-emergent adverse events in Phase 1b/2a Participants with at least one TEAE 9 (69%) • In the Phase 1b/2a of IMG-007 in moderate- to-severe AD there were Study treatment related TEAEs 0 • No serious a
Slide 17: Th1, Th2, and Th17 biomarkers reduced to within healthy volunteer ranges
Th1, Th2, and Th17 biomarkers were reduced to within healthy volunteer ranges in IMG-007 treated AD patients in the Phase 1b/2a proof-of-concept study Th2 serum proteins Th17 serum proteins Th1 serum proteins th 50 percentile th of healthy 50 percentile th subjects of healthy 50 percentile subjects
Slide 18: ADAPTIVE: the IMG-007 phase 2b clinical trial in atopic dermatitis
ADAPTIVE: the IMG-007 phase 2b clinical trial in atopic dermatitis (AD) The phase 2b ADAPTIVE trial is a randomized, double-blind, placebo-controlled dose-finding study of IMG-007 in adults with moderate-to-severe AD, recruiting both biologic- and/or JAK inhibitor-experienced and naive patients and
Slide 19: IMG-007 has pipeline-in-a-product growth potential
IMG-007 has pipeline-in-a-product growth potential Inflamm- Rheumatoid Multiple atory Atopic $10 billion+ arthritis sclerosis bowel dermatitis markets each disease Systemic lupus Type 1 Asthma $5-10 billion (biologics) erythemat diabetes markets each osus Alopecia Systemic Prurigo Myasthenia Hidrade
Slide 20: IMG-007 has shown proof-of-concept in a second indication: alopecia areata
IMG-007 has shown proof-of-concept in a second indication: alopecia areata • Alopecia areata (AA): chronic autoimmune Alopecia areata is a difficult, disease characterized by hair loss chronic autoimmune disease with • OX40 association: Upregulation of OX40 / high unmet need; People OX40L in the sca
Slide 21: IMG-007 was well tolerated in a second proof-of-concept study in alopecia areata
IMG-007 was well tolerated in a second proof-of-concept study in alopecia areata (AA) IMG-007 AA Phase 1b/2a patient demographics IMG-007 AA Phase 1b/2a treatment-emergent IMG-007 300mg IMG-007 600mg Demographic/Baseline N=6 N=23 adverse events occurring in two or more patients Ethnicity, n (%) Whit
Slide 22: Four-week IMG-007 treatment resulted in SALT score improvement
Four-week IMG-007 treatment resulted in SALT score improvement, with marked improvement in AA patients with baseline SALT score 50 to <95 Mean % change from baseline in SALT score Mean % change from baseline in SALT score by dose by baseline disease severity (600mg) IMG-007 300 mg (N=6) IMG-007 600
Slide 23: Photographs of select AA patients showed hair regrowth
Photographs of select AA patients after treatment with three IMG-007 doses showed hair regrowth Baseline Week 24 Week 16 Week 24 Week 36 Baseline Week 24 Baseline All three patients treated with 600mg doses at weeks 0, 2, and 4 23 Patient 1 Patient 2 Patient 3
Slide 24: IMG-007 value creation trajectory; well resourced to execute AD Phase 2b study
IMG-007 value creation trajectory; well resourced to execute AD Phase 2b study IMG-007 designed Build value: with a trifecta Focus on execution, raise company profile, drive IMG-007 of differentiating POC data in AD shows Phase 2b forward features promising EASI score changes and favorable Build val
Slide 25: “magene
SB, “magene